ATWLPPRPeptideTFA是一种选择性的neuropilin-1(NRP-1)抑制剂，能够抑制VEGF165与NRP-1结合，可用于血管生成的研究。ATWLPPRPeptideTFA能够减轻糖尿病引起的早期视网膜损伤。
货号:ajcx13176
CAS:N/A
分子式:C42H62F3N11O11
分子量：954
溶解度:H2O : ≥ 50 mg/mL (52.41 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes[2].

ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1 by 82% at 100 μM[1].

ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes[2].ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) in the retina[2].

[1]. Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402. [2]. Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571.